PureTech Health plc's chief innovation and strategy officer, Eric Elenko, and president, Bharatt Chowrira, disclose details about the company's decision to develop a new schizophrenia therapy that could potentially alter the market – but can the model be repeated?
Founded by PureTech in 2009, Karuna Therapeutics, Inc. went public in 2019 and was acquired by Bristol Myers Squibb for $14bn in December 2023. KarXT (xanomeline-trospium), its lead asset, is an oral, investigational muscarinic agonist with a unique mechanism of action and differentiated efficacy and safety
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?